Multiple Myeloma Market to Observe Impressive Growth at a CAGR of ~5% During the Study Period (2019-2032), Assesses DelveInsight

The dynamics of the multiple myeloma market are anticipated to change in the coming years owing to the rise in novel drugs and therapies and the number of healthcare spending across the world. Key players, such as Janssen, Bristol Myers Squibb, Pfizer, Regeneron Pharmaceuticals, AbbVie, Roche,  and others are involved in developing drugs for multiple myeloma.

LAS VEGAS, Aug. 14, 2023 /PRNewswire/ -- DelveInsight's Multiple Myeloma Market Insights report includes a comprehensive understanding of current treatment practices, multiple myeloma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Multiple Myeloma Market Report

• As per DelveInsight analysis, the multiple myeloma market size in the United States was approximately USD 14 billion in 2022.
• According to the assessment done by DelveInsight, the estimated total incident multiple myeloma cases in the 7MM were approximately 65,500 in 2022. 
• Leading multiple myeloma companies such as Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, and others are developing novel multiple myeloma drugs that can be available in the multiple myeloma market in the coming years.
• The promising multiple myeloma therapies in the pipeline include Talquetamab, Elranatamab, VENCLEXTA (venetoclax), Linvoseltamab, Iberdomide (CC-220), Mezigdomide (CC-92480), Cevostamab, CART-ddBCMA, PHE885, REGN5459, BGB-11417, Zevorcabtagene Autoleucel, Descartes-11, CFT7455, HDP-101, Orvacabtagene Autoleucel, RAPA-201 Autologous Cell Therapy, ABBV-383 (TNB-383B), Modakafusp (TAK-573), and others.
• Multiple myeloma treatment landscape is evolving with the rise of monoclonal antibodies being used in newly-diagnosed patients. DARZALEX's position is strong, in comparison to its competitors in the market. There is a some degree of likelihood that many other drugs currently being evaluated for the treatment of multiple myeloma market will work together with DARZALEX rather than directly competing with it. J&J is exploring to sequence DARZALEX with TECVAYLI, CARVYKTI, and talquetamab.
• A second CD38 antibody called SARCLISA has been approved for the treatment of multiple myeloma. SARCLISA continues its rapid acceptance in key markets. But DARZALEX has an advantage over SARCLISA of more than four years. Both monoclonal antibodies are competing against one another in a quadruplet regimen and are close to a final showdown in transplant-eligible and ineligible settings.
• By 2025, at least five new therapies are anticipated to be available in the United States, including three bispecific antibodies (Elranatamab, Talquetamab, and Linvoseltamab), one CAR-T (Zevorcabtagene autoleucel), and one BCL-2 inhibitor (Venetoclax).

Discover which therapies are expected to grab the major multiple myeloma market share @ Multiple Myeloma Market Report

Multiple Myeloma Overview

Multiple myeloma is a type of cancer that affects plasma cells, which are a vital component of the immune system. These plasma cells, normally responsible for producing antibodies to fight infections, become malignant and uncontrollably multiply, leading to the formation of cancerous tumors in bone marrow and interfering with the production of healthy blood cells. The exact cause of multiple myeloma remains unclear, but several risk factors have been identified. 

Symptoms of multiple myeloma can vary, and some individuals may experience no symptoms in the early stages. Common signs include bone pain, especially in the back or ribs, as the cancerous cells infiltrate the bone marrow. Patients may also suffer from frequent infections due to a weakened immune system, fatigue, anemia, kidney problems, and unexplained fractures. Diagnosing multiple myeloma involves several key steps. Initially, a medical history and physical examination are conducted, paying attention to symptoms and risk factors.

Multiple Myeloma Epidemiology Segmentation

• The total number of symptomatic cases of multiple myeloma in the US was ~32,000 in 2022.
• Multiple myeloma is more common in males as compared to females. In the United States, more than 50% of males are diagnosed with multiple myeloma.
• Data suggests that roughly half of the newly diagnosed multiple myeloma patients are eligible for transplant; however, around a third of eligible patients end up not receiving the transplant. Approximately 30% of patients received SCT annually in the United States. 

The multiple myeloma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Multiple Myeloma Incident Cases
• Total Multiple Myeloma Symptomatic Cases
• Multiple Myeloma Gender-Specific Cases
• Multiple Myeloma Age-Specific Cases
• Multiple Myeloma Transplant Eligible and Ineligible Cases
• Treated Cases Across the Lines of Therapies

Multiple Myeloma Treatment Market 

The management of multiple myeloma is individualized based on factors such as the stage of the disease, the patient's overall health, and their specific genetic characteristics. Common multiple myeloma treatment options include chemotherapy, immunomodulatory drugs, and stem cell transplantation. Chemotherapy is often used to reduce the number of myeloma cells and control disease progression. Immunomodulatory drugs, such as lenalidomide and thalidomide, help enhance the body's immune response against cancer cells. Proteasome inhibitors like bortezomib and carfilzomib, specifically target the abnormal cells and inhibit their growth and survival.

For eligible patients, stem cell transplantation can be a crucial part of the treatment. Autologous stem cell transplantation, where the patient's own stem cells are collected and then infused back after high-dose chemotherapy, can help achieve deeper remissions and prolong survival. In recent years, advancements in multiple myeloma treatment have led to the approval of novel therapies, such as monoclonal antibodies like daratumumab and elotuzumab, CAR-Ts like ABECMA and CARVYKTI, and bispecific antibody like TECVAYLI which further enhance the treatment landscape.

The treatment of multiple myeloma is continually evolving as researchers and clinicians work to improve outcomes and enhance the quality of life for patients. As with any cancer, early detection and a multidisciplinary approach remain vital in providing the best possible care and improving overall prognosis. Patients are encouraged to work closely with their healthcare team to determine the most appropriate treatment plan for their specific condition.

To know more about multiple myeloma treatment guidelines, visit @ Multiple Myeloma Management 

Multiple Myeloma Pipeline Therapies and Key Companies

• Talquetamab: Johnson & Johnson (Janssen)
• Elranatamab: Pfizer
• VENCLEXTA (venetoclax): AbbVie and Roche (Genentech)
• Linvoseltamab: Regeneron Pharmaceuticals
• Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
• Mezigdomide (CC-92480): Bristol-Myers Squibb/Celgene
• Cevostamab: Roche (Genentech)
• CART-ddBCMA: Arcellx
• PHE885: Novartis
• REGN5459: Regeneron Pharmaceuticals
• BGB-11417: BeiGene
• Zevorcabtagene Autoleucel: CARsgen Therapeutics
• Descartes-11: Cartesian Therapeutics
• CFT7455: C4 Therapeutics
• HDP-101: Heidelberg Pharma
• Orvacabtagene Autoleucel: Bristol-Myers Squibb
• RAPA-201 Autologous Cell Therapy: RAPA Therapeutics
• ABBV-383 (TNB-383B): AbbVie (TeneoOne)
• Modakafusp (TAK-573): Takeda

Learn more about the FDA-approved drugs for multiple myeloma @ Drugs for Multiple Myeloma Treatment 

Multiple Myeloma Market Dynamics

Over the years, the multiple myeloma market has seen substantial growth due to advancements in medical research, improved diagnostic technologies, and the introduction of novel therapies. One of the key drivers of the multiple myeloma market has been the development and approval of innovative treatments. Immunotherapies and monoclonal antibodies have shown promising results in clinical trials, leading to their adoption as standard treatments for the disease. These advancements have significantly improved patient outcomes and survival rates.

Additionally, increasing awareness of multiple myeloma among both patients and healthcare professionals has resulted in earlier diagnosis and treatment initiation, which is crucial for better disease management. Moreover, the growing elderly population, as multiple myeloma primarily affects older individuals, has contributed to the expansion of the multiple myeloma market.

However, despite these positive developments, challenges remain in the multiple myeloma market. The high cost of some of the newer therapies can limit access for patients, raising concerns about affordability and reimbursement. Moreover, as competition intensifies, drug manufacturers need to focus on demonstrating their therapies' superior efficacy and safety profiles to gain a competitive edge. Furthermore, ongoing research efforts are continuously uncovering new insights into the disease's biology and potential therapeutic targets. These discoveries may lead to the development of more innovative treatment approaches, further shaping the dynamics of the multiple myeloma market.

Scope of the Multiple Myeloma Market Report

• Therapeutic Assessment: Multiple Myeloma current marketed and emerging therapies
• Multiple Myeloma Market Dynamics: Key Market Forecast Assumptions of Emerging Multiple Myeloma Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Multiple Myeloma Market Access and Reimbursement

Discover more about multiple myeloma drugs in development @ Multiple Myeloma Clinical Trials

Table of Contents

Related Reports

Multiple Myeloma Epidemiology Forecast

Multiple Myeloma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and multiple myeloma epidemiology trends.

Multiple Myeloma Pipeline

Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Janssen, Pharmacyclics, Novartis, Incyte Corporation, Gracell Biotechnology, SpringWorks Therapeutics, Sana Biotechnology, Cytovia Therapeutics, Pfizer, MorphoSys, Biokine Therapeutics, Arcellx, Rapa Therapeutics, iTeos Therapeutics, Sorrento Therapeutics, CARsgen, Ascentage Pharma, Cartesian Therapeutics, Bristol-Myers Squibb, Juno Therapeutics, Nanjing IASO Biotherapeutics, Arch Oncology, Oncoceutics, TeneoBio, Nerviano Medical Sciences, among others.

Relapse/Refractory Multiple Myeloma Market

Relapse/Refractory Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key R/R multiple myeloma companies, including NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com   
+1(919)321-6187
www.delveinsight.com   

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg